Appropriate Risk Classification and Low-Dose Rituximab May Help Prevent Acute Rejection in ABO-Compatible Living Kidney Transplantation
Transplantation Proceedings · 2026-07 · 58 (6) · 1014-1021
DOI: 10.1016/j.transproceed.2026.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2026-07. Verfasst von Miruzato Fukuda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Renal Surgery, Toranomon Hospital, Tokyo, Japan. Electronic address: mirumiru9201@gmail.com. Hauptthemen laut MEDLINE: Rituximab, Kidney Transplantation, Graft Rejection, ABO Blood-Group System. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Rituximab desensitization improves outcomes in ABO-incompatible (ABOi) kidney transplantation, and a fixed dose of 200 mg has been shown to prevent antibody-mediated rejection with fewer infections. Although the risk of ABO-compatible (ABOc) transplants is generally low, acute rejection still occurs, suggesting undetected antibodies. Previous studies on ABOc have emphasized conventional dosing or universal administration in non-sensitized recipients, without individualized stratification. We assessed low-dose rituximab in ABOc recipients and propose a preoperative risk-classification framework. METHODS: We retrospectively reviewed 264 living-donor kidney transplants between January 2015 and July 2024. After excluding ABOi transplants and cases involving double-filtration plasmapheresis/intravenous immunoglobulin, 158 ABOc recipients were included. Recipients were stratified into rituximab (n = 28; single 200 mg dose 14 days before transplant) and rituximab-free (n = 130) groups. The primary endpoints were 1-year acute rejection and infections. RESULTS: The rituximab group had a higher immunologic risk, with fewer related donors (32.1% vs 66.2%; p = .002), and more sensitized (67.9% vs 39.2%; p = .011) or donor-specific antibody (DSA)-positive (17.9% vs 1.5%; p = .001) recipients. Despite this, 1-year acute rejection was lower (0% (0/28) vs 10.8% (14/130); p = .133), with a trend toward improved rejection-free survival (log-rank p = .075), and 1-year infection rates were similar (21.4% vs 23.1%; p = 1.0; log-rank p = .83). In the DSA-positive subgroup (rituximab n = 5; control n = 2), all treated patients remained rejection-free, whereas both untreated patients developed rejection. CONCLUSIONS: In ABOc recipients, risk-stratified preoperative low-dose rituximab may help prevent rejection without increasing infections. Our proposed risk-stratification framework may guide patient selection, but these preliminary findings require validation in larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Renal Surgery, Toranomon Hospital, Tokyo, Japan. Electronic address: mirumiru9201@gmail.com.
- Center of Renal Surgery, Toranomon Hospital, Tokyo, Japan.
- Center of Renal Surgery, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Zitieren
APA
Fukuda, M., Yokoyama, T., Miki, K., Tanaka, K., Kamiyama, M., Nakamura, Y., & Ishii, Y. (2026). Appropriate Risk Classification and Low-Dose Rituximab May Help Prevent Acute Rejection in ABO-Compatible Living Kidney Transplantation. Transplantation Proceedings, 58(6), 1014-1021. https://doi.org/10.1016/j.transproceed.2026.06.010
Vancouver
Fukuda M, Yokoyama T, Miki K, Tanaka K, Kamiyama M, Nakamura Y, et al. Appropriate Risk Classification and Low-Dose Rituximab May Help Prevent Acute Rejection in ABO-Compatible Living Kidney Transplantation. Transplantation Proceedings. 2026;58(6):1014-1021. doi:10.1016/j.transproceed.2026.06.010
BibTeX
@article{Fukuda2026,
author = {Fukuda, Miruzato and Yokoyama, Takayoshi and Miki, Katsuyuki and Tanaka, Kiho and Kamiyama, Manabu and Nakamura, Yuki and Ishii, Yasuo},
title = {Appropriate Risk Classification and Low-Dose Rituximab May Help Prevent Acute Rejection in ABO-Compatible Living Kidney Transplantation},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {6},
pages = {1014--1021},
doi = {10.1016/j.transproceed.2026.06.010}
}
EUVIMED